Related Experiment Video

Updated: Dec 26, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
08:41

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2

Published on: November 5, 2021

3.2K

[Pharmacotherapeutics for the new coronavirus pneumonia]

B Du1, H B Qiu2, X Zhan3

  • 1Medical ICU, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing 100730, China.

Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases
|March 13, 2020
PubMed

Insights

This review shares therapeutic experiences for treating new coronavirus pneumonia (NCP), also known as COVID-19. Current recommendations include Ribavirin and interferon-α, with further research needed for Lopinavir/Ritonavir and Remdesivir.

Area of Science:

  • Medicine
  • Infectious Diseases
  • Public Health

Background:

  • The novel coronavirus pneumonia (NCP), designated COVID-19, emerged as a severe global health crisis in early 2020.
  • Over 40,000 cases were reported, highlighting the unprecedented and rapid spread of this novel coronavirus (n-Cov).
  • Existing studies on COVID-19 were limited to single-center or retrospective analyses.

Purpose of the Study:

  • To review and share therapeutic experiences for managing COVID-19 based on available literature.
  • To provide insights into current treatment strategies and recommendations for NCP.

Main Methods:

  • Literature review of therapeutic interventions for COVID-19.
  • Analysis of treatment guidelines and emerging evidence.

Main Results:

  • The 5th edition National Health Commission's Regimen recommends combining Ribavirin and interferon-α for NCP treatment, drawing from MERS treatment protocols.
  • The efficacy of Lopinavir/Ritonavir and Remdesivir requires confirmation through randomized controlled trials (RCTs) due to the absence of specific antiviral drugs for COVID-19.
  • Short-term systemic glucocorticosteroid use is suggested, but RCTs are needed to validate its effectiveness.

Conclusions:

  • Current treatment strategies for COVID-19 involve established antiviral combinations and cautious use of glucocorticosteroids.
  • Avoidance of inappropriate antibiotic use is crucial, as bacterial co-infection is uncommon in COVID-19 patients.
  • Further rigorous clinical trials, particularly RCTs, are essential to establish definitive treatment protocols for COVID-19.

Keywords:
AntibioticsGlucocorticosteroidNew coronavirus pneumoniaPharmacotherapeutics

More Related Videos

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

15.1K
Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.7K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
677
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
3.3K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
934
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
379
Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
555
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
3.0K